Shanghai Enkai Cell Technology Co., Ltd.
PrivateLast Round
VC Round
Jul 9, 2025
Total Funding Raised
$15M
Company Overview
Shanghai Enkai Cell Technology Co., Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a VC Round in July 2025.
Shanghai Enkai Cell Technology Co., Ltd. is a biotechnology company that develops innovative NK (Natural Killer) cell therapies for the treatment of tumors and other major clinical diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Enkai Cell Technology Co., Ltd. Comparables
Compare Shanghai Enkai Cell Technology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NK:IO | 84% | |
| Neukio Biotherapeutics | 83% | |
| Indapta Therapeutics | 83% |
For institutional investors. Book with your work email.
Shanghai Enkai Cell Technology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jul 9, 2025 | ||||
| VC Round | Nov 22, 2024 | ||||
| VC Round | Jun 3, 2023 | ||||
| Series A | Jul 1, 2022 | ||||
| Angel | Nov 19, 2021 |
For institutional investors. Book with your work email.
Shanghai Enkai Cell Technology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Beijing Fangfu Venture Capital Management | VC Round |
| 乔景资本 (QJ Capital) | Series A |
| Huagai Capital | Series A |
| Unifortune | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 22, 2024
3SBio Inc led the latest VC round.
- Jun 3, 2023
Raised a VC Round with Beijing Fangfu Venture Capital Management.
For institutional investors. Book with your work email.
Shanghai Enkai Cell Technology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai Enkai Cell Technology Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai Enkai Cell Technology Co., Ltd. a public or private company?
Shanghai Enkai Cell Technology Co., Ltd. is a private company.
What is the current stock price of Shanghai Enkai Cell Technology Co., Ltd.?
Shanghai Enkai Cell Technology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Shanghai Enkai Cell Technology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai Enkai Cell Technology Co., Ltd. worth (valuation)?
Valuation information for Shanghai Enkai Cell Technology Co., Ltd. is not publicly available.
Can I buy Shanghai Enkai Cell Technology Co., Ltd. stock?
Shanghai Enkai Cell Technology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai Enkai Cell Technology Co., Ltd.'s last funding round?
Shanghai Enkai Cell Technology Co., Ltd.'s most recent funding round was VC Round on July 9, 2025.
Who are the main investors in Shanghai Enkai Cell Technology Co., Ltd.?
Key investors in Shanghai Enkai Cell Technology Co., Ltd. include Huagai Capital.
Will Shanghai Enkai Cell Technology Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai Enkai Cell Technology Co., Ltd..
How can I track Shanghai Enkai Cell Technology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai Enkai Cell Technology Co., Ltd.'s shares on secondary markets.